Steamboat Capital Partners Reveals 7.1% Medifast Stake After $8.4M Buying Spree
MED sits 30% above its 52-week low of $9.22.
Summary
Steamboat Capital Partners and Parsa Kiai disclosed a 7.1% stake in Medifast, acquired for approximately $8.4 million through open market purchases, including recent buys on August 19-20, 2026.
Key Events · Ownership and Investor Activity · MED
-
7.1% Stake Disclosed
Steamboat Capital Partners and Parsa Kiai report beneficial ownership of 790,693 shares, representing 7.1% of Medifast's outstanding common stock.
-
Total Investment of $8.4M
The shares were acquired at an aggregate price of approximately $8,360,835, funded by working capital of clients, including investment funds.
-
Recent Open Market Purchases
On August 19-20, 2026, the reporting persons bought 83,994 shares at weighted average prices of $11.66 and $11.60 per share, respectively.
-
Activist Investor Profile
Steamboat Capital Partners is an investment adviser (IA) and Parsa Kiai is its managing member, indicating a professional investor with potential influence over company strategy.
Analysis · MED · Manufacturing
A 7.1% stake in Medifast has been accumulated by Steamboat Capital Partners, led by Parsa Kiai, through open market purchases totaling approximately $8.4 million. The most recent buys, on August 19-20, 2026, added 83,994 shares at prices near $11.60-$11.66. This accumulation comes amid a challenging period for Medifast, which recently reported a 27.6% revenue decline and a net loss for Q2 2026. The stake signals conviction from an activist-oriented investor, though the filing does not disclose any specific plans or proposals.
At the time of this filing, MED was trading at $11.95 on NYSE in the Manufacturing sector, with a market capitalization of approximately $133.6M. The 52-week trading range was $9.22 to $14.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.